Cost implications of the use of ramipril in high-risk patients based on the heart outcomes prevention evaluation (HOPE) study

Circulation

Volumn 107, Issue 7, 2003, Pages 960-965

  Lamy, Andre ^a,b,c   Yusuf, Salim ^a,b   Pogue, Janice ^a,b   Gafni, Amiram ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Cardiovascular diseases; Cerebrovascular disorders; Cost benefit analysis; Diabetes mellitus; Trials

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; PLACEBO; RAMIPRIL;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH CARE FINANCING; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTICENTER STUDY; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; UNITED STATES;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CANADA; CEREBROVASCULAR ACCIDENT; COST-BENEFIT ANALYSIS; DRUG COSTS; HEALTH CARE COSTS; HEART DISEASES; HOSPITALIZATION; HUMANS; MULTICENTER STUDIES; MYOCARDIAL INFARCTION; PLACEBOS; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS; RISK; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; UNITED STATES;

EID: 0037465370     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000050600.49419.25     Document Type: Article

References (16)

1. Lonn EM, Yusuf S, Jha P, et al. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994:90:2056-2069.
2. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensinconverting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
3. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and Vitamin E in patients at high risk of cardiovascular events. Can J Cardiol. 1996;12:127-137.
4. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
5. Francis GS. ACE inhibition in cardiovascular disease. N Engl J Med. 2000;342:201-202.
6. Centers for Medicare and Medicaid Services. Medicare provider analysis and review (MEDPAR) of short-stay hospitals. Available at: http://cms.hhs.gov/statistics/medpar/default.asp. Accessed January 25, 2003.
7. Kirschner C, Kopacz J, Reyes D. Current Procedural Terminology: CPT 2001. 4th ed. Chicago, Ill: American Medical Association; 2000:645.
8. Holloway RG, Witter DM, Lawton MA, et al. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46:854-860.
9. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 1999;159:1873-1880.
10. Medical Economics Company. Drug Topics Red Book. New Jersey: Medical Economics Co; 1999.
11. Smith KM, Lamy A, Arthur HM, et al. Outcomes and costs of coronary artery bypass grafting: comparison between octogenarians and septuagenarians at a tertiary care centre. CMAJ. 2001;165:759-764.
12. Ontario Case Cost Project (OCCP). Ontario Guide to Case Costing, Version 1.1. Ottawa: Ontario Case Cost Project; 1995.
13. Briggs A, Gray A. The distribution of health care costs and their statistical analysis for economic evaluation. J Health Serv Res Policy. 1998;3:233-245.
14. Carpenter J. Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Stat Med. 2000;19:1141-1164.
15. Gold MR, Siegel JE, Russel LB, et al. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
16. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. 2nd ed. Oxford: Oxford Medical Publication; 1997:296.